Longer-Term Efficacy and Safety of Zodasiran in Patients with Mixed Hyperlipidaemia
Clicks: 7
ID: 322273
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
7 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #68 of 192 articles by views in european journal of preventive cardiology
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 192 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
BACKGROUND: Mixed hyperlipidaemia, characterized by elevated cholesterol and triglyceride levels, is associated with increased risk of atherosclerotic cardiovascular disease (ASCVD). Angiopoietin-like protein 3 (ANGPTL3) regulates lipid metabolism through inhibition of lipoprotein and endothelial lipases. Loss-of-function variants in ANGPTL3 are associated with lower plasma triglycerides, cholesterol, and reduced ASCVD risk. Zodasiran, a hepatocyte-targeted small interfering RNA (siRNA) against ANGPTL3, demonstrated significant lipid lowering in the Phase 2b ARCHES-2 trial. AIMS: To evaluate the long-term safety and efficacy of zodasiran in adults with mixed hyperlipidaemia participating in the open-label extension (OLE) of ARCHES-2 (NCT04832971). METHODS: Adults with mixed hyperlipidaemia (fasting triglycerides 1.7-5.6 mmol/L and LDL-C ≥ 1.8 mmol/L or non-HDL-C ≥ 2.59 mmol/L) who completed 9 months of randomised treatment with placebo or zodasiran (50-, 100-, or 200-mg subcutaneously Q3 M) were eligible for the OLE. The primary endpoint in the randomised doubleblind study was percent change in median triglycerides from baseline to Month 6. Here, lipid parameters were assessed through 21 months of the OLE; with total follow-up of 24 months. RESULTS: Of 191 participants completing randomised treatment, 156 (82%) enrolled in the OLE. Over 24 months, zodasiran was generally well tolerated; five participants (3.2%) discontinued due to adverse events; one (0.6%) death, not considered treatment-related, occurred. Injection site reactions were mild. By Month 21, median triglycerides were reduced by -55% (95% CI, 64, 43); remnant cholesterol by -57% (SD: 32); LDL-C by -5% (SD: 40); and ApoB by -13% (SD: 21). CONCLUSIONS: Zodasiran produced sustained reductions in triglycerides and atherogenic lipoproteins over 30 months and was well tolerated, supporting its potential as a long-term therapeutic option for mixed hyperlipidaemia.
| Reference Key |
openalex_W7170703574
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Robert S. Rosenson, Daniel Gaudet, Christie M. Ballantyne, Stephen J. Nicholls, Kathryn Jean Lucas, Nicholas J Leeper, Rong Zhou, Lar Aiyer, Jennifer Hellawell, Gerald F Watts |
| Journal | european journal of preventive cardiology |
| Year | 2026 |
| DOI |
10.1093/eurjpc/zwag376
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.